Fundraising Fox
/Companies
Sign in

Cellares

South San Francisco, US · Founded 2019 · Delaware corporation · 332 employees on LinkedIn · 17 known investors

Find your way into Cellares

Sign up to see every warm intro you have to Cellares

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Cellares team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Cellares develops automated manufacturing systems and technology platforms to accelerate the production and commercialization of cell therapies. The company serves biopharmaceutical manufacturers and cell therapy developers worldwide.

Advanced ManufacturingBiotechMedical Devices

Founders & leadership

Cellares was founded in 2019 by Fabian Gerlinghaus and Omar Kurdi.

FGFabian Gerlinghaus
Fabian GerlinghausFounderFabian Gerlinghaus is Co-Founder and CEO of Cellares, which builds automated manufacturing platforms for cell therapy production. He was previously Chief Innovation Officer at Synthego, where he co-developed the company's RNA synthesizer technology, and holds a master's in aerospace engineering from the Technical University of Munich and an honours degree in technology management from the Center for Digital Technology and Management, Munich.
OKOmar Kurdi
Omar KurdiFounderOmar Kurdi is Co-Founder and President of Cellares, which develops automated manufacturing systems and platforms for producing cell therapies. He has a background in engineering and operations, with experience in strategic planning, business development, startup and large-scale manufacturing operations, Lean methodologies, and GMP/ISO 13485/FDA regulatory compliance.
AP
Alex PeschFounder
FG
Fabian Gerlinghaus Omar KurdiFounder

Board

JBJustin Butler
Justin ButlerBoard Member2019–2025Partner at Eclipse Ventures
VTVictor Tong
Victor TongBoard directorManaging Director at Decheng Capital

Investors · 17

8VClisted by 8VCAustin · $500K – $50M

How we know: 8VC's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

EcoR1 Capitallisted by EcoR1 CapitalSan Francisco
Intuitive Ventureslisted by Intuitive VenturesSunnyvale

How we know: cellares.com · Not right? Tell us

Koch Disruptive Technologieslisted by Koch Disruptive TechnologiesSan Francisco
Baillie GiffordreportedEdinburgh

How we know: funding news · cellares.com · Not right? Tell us

BlackRockreportedNew York

How we know: cellares.com · Not right? Tell us

EclipsereportedPalo Alto

How we know: funding news · cellares.com · Not right? Tell us

Eclipse VenturesreportedPalo Alto · $200K – $5M

How we know: a partner's Signal profile · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

T. Rowe PricereportedBaltimore

How we know: cellares.com · Not right? Tell us

Willett AdvisorsreportedNew York

How we know: cellares.com · Not right? Tell us

Also in the syndicate · 6

DC Global VenturesDFJ GrowthDuquesne Family OfficeEDBIGates FrontierPrime Radiant Partners

Funding

SEC filings, press & company announcements

$389M disclosed across 3 of 5 rounds · 2021–2026

▶$82MraisedMay 2021 · 9 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Justin ButlerDirector
  • Fabian GerlinghausExecutive Officer, Director
  • Victor TongDirector
  • Omar KurdiExecutive Officer, Director
Offering amount
$82M
Amount sold
$82M
First sale
Apr 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

CelularityCelularity is a regenerative and cellular medicine company developing and commercializing biomaterial products and allogeneic, cryopreserved cell therapies derived from the postpartum placenta to target age-related diseases. It operates its own integrated manufacturing, translational research, and biobanking facility for placenta-derived cellular medicines and advanced biomaterials.

Companies working in the same space as Cellares.

In the news

Cellares Raises $327M in Series D Fundingfinsmes.com · Jun 2026Cellares Raises $257 Million Series D Led by BlackRock and Eclipse to Industrialize Global Cell Therapy Manufacturing with Breakthrough Automation - Cellarescellares.com · Jan 2026

Frequently asked questions

What does Cellares do?
Cellares develops automated manufacturing systems and technology platforms to accelerate the production and commercialization of cell therapies. The company serves biopharmaceutical manufacturers and cell therapy developers worldwide.
Who founded Cellares?
Cellares was founded by Fabian Gerlinghaus, Omar Kurdi in 2019.
Who are Cellares's investors?
Cellares's investors include Decheng Capital, 8VC, EcoR1 Capital, Intuitive Ventures, Koch Disruptive Technologies, Baillie Gifford, BlackRock, Eclipse and 3 more.
How much funding has Cellares raised?
Cellares has disclosed $389M raised across 3 of its 5 known rounds.
Where is Cellares headquartered?
Cellares is headquartered in South San Francisco, US.